The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration, also known as age-related macular degeneration ... Macular degeneration occurs as cells within the retinal pigment epithelium (RPE) degrade and die. The RPE is a layer ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.0, along with a high estimate of $9.00 and a low estimate of $2.00. No alteration is ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at ...

Age-related macular degeneration (AMD) has three stages: early, intermediate, and late stage. Vision loss usually happens in the last stage of AMD. However, not everyone with AMD progresses through ...

Researchers at the USC Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute are advancing a new treatment for dry age-related macular degeneration ... of a stem cell-derived ...

The most common retinal disease among the aging population is age-related macular degeneration (AMD), accounting for approximately ... An early form of AMD, known as dry AMD, makes up approximately 90 ...

Confocal color imaging, green autofluorescence, and OCT are preferred for GA evaluation, each with unique benefits and drawbacks. Autofluorescence offers precise GA delineation but may cause patient ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to ...

The Indian biotech company’s lead product, called EyeCyte-RPE, is aimed at treating geographic atrophy, an advanced form of dry age-related macular degeneration ... Because dry AMD leads to a loss of ...